FY2025 · ended Dec 31, 2025 · Revenue $32.38M, +20.3% YoY · Filed Mar 12, 2026
Stereotaxis, Inc. (STXS) files with the SEC under industry code 3845, Electromedical & Electrotherapeutic Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $32.4 million and a net loss of $21.6 million. Free cash flow was -$13.8 million. As of Jun 30, 2026 it held $10.5 million in cash and investments and $5.2 million in total debt.
Revenue (TTM)
$30.07M
-5.5% vs year-ago TTM
Net income (TTM)
$-22.32M
+4.4% vs year-ago TTM
Operating cash flow (TTM)
$-15.29M
-78.3% vs year-ago TTM
Free cash flow (TTM)
$-15.50M
-80.1% vs year-ago TTM
EPS (TTM)
$-0.24
+13.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
97.25M
+13.1% vs prior year
Net cash
$5.32M
as of Jun 30, 2026
Operating margin
-75.7%
FY 2026
Company profile
- Industry
- Electromedical & Electrotherapeutic Apparatus (SIC 3845)
- Listed as
- STXS (NYSE)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- St.Louis, MO
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1289340
Other Electromedical & Electrotherapeutic Apparatus companies
- Medtronic plc MDT
- LivaNova PLC LIVN
- Integer Holdings Corp ITGR
- Axogen, Inc. AXGN
- TransMedics Group, Inc. TMDX
- CONMED Corp CNMD
- Ceribell, Inc. CBLL
- InMode Ltd. INMD
All 31 Electromedical & Electrotherapeutic Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $32.4M | $26.9M | $26.8M | $28.1M | $35.0M |
| Operating income | -$22.1M | -$24.7M | -$21.8M | -$18.8M | -$12.9M |
| Net income | -$21.6M | -$24.0M | -$20.7M | -$18.3M | -$10.7M |
| Diluted EPS | -$0.25 | -$0.30 | -$0.27 | -$0.26 | -$0.16 |
| Operating cash flow | -$13.7M | -$8.5M | -$9.1M | -$8.4M | -$2.9M |
| Free cash flow | -$13.8M | -$8.5M | -$9.5M | -$10.8M | -$4.3M |
| Total assets | $52.3M | $46.7M | $41.9M | $53.4M | $61.0M |
| Total liabilities | $33.5M | $35.3M | $20.0M | $21.5M | $21.6M |
| Stockholders' equity | $13.5M | $6.1M | $16.3M | $26.3M | $33.8M |
| Cash and investments | $13.4M | $12.2M | $19.8M | $28.4M | $38.7M |
| Total debt | $5.4M | $6.0M | $5.5M | $5.9M | $6.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Other events
|
Jul 16, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Unregistered share sale, Regulation FD disclosure, Other events
|
Jul 9, 2026 | Jul 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 15, 2026 | May 14, 2026 |
| 10-Q | Quarterly report | May 13, 2026 | Mar 31, 2026 |
All 1003 Stereotaxis, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.